Zafonte et al. (2012)
Population: TBI; Age Range=18-70yr; Gender: Male=903, Female=310; Severity: Moderate/Severe=406, Complicated Mild=807.
Treatment: Patients received either citicoline (n=607; 2000mg/d) or a placebo (n=606) via enteral route, initiated within 24h of injury. This continued for 90d.
Outcome Measure: TBI-Clinical Trials Network Core Battery: Trials Making Tests A&B, Glasgow Outcome Scale-Extended (GOS-E), Controlled Oral Word Associated Test, California Verbal Learning Test II, Processing Speed Index, Digit Span, Stroop Test.
- At the 90 d evaluation, no differences were found between the two groups on the TBI-Clinical Trials Network Core Battery (global OR, 0.98; 95% Ci, 0.38-1.15).
- Rates of favourable improvement were 35.4% and 35.6% on the GOS-E for the treatment and control group, respectively.
- Results from the remaining test also showed similar levels of improvement between the groups, with rates of improvement in the treatment group ranging from 37.3% to 86.5% and the control from 42.7% to 84.0%.